ENDRA Life Sciences (NDRA) EBT (2016 - 2026)

ENDRA Life Sciences (NDRA) has reported EBT for 11 consecutive years, with $159944.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBT rose 113.05% year-over-year to $159944.0 in Q2 2026; TTM through Jun 2026 was -$5.9 million, a 32.5% increase from a year earlier, with the FY2025 full-year figure at -$7.0 million, up 38.93% from the prior year.
• EBT was $159944.0 for Q2 2026 at ENDRA Life Sciences, up from -$1.3 million in the prior quarter.
• Over five years, EBT peaked at $159944.0 in Q2 2026 and troughed at -$4.1 million in Q4 2024.
• A 5-year average of -$2.4 million and a median of -$2.7 million in 2023 frame the typical range for EBT.
• Across the five-year window, EBT plunged 184.27% in 2024 and jumped 113.05% in 2026, its largest moves.
• Over 5 years, EBT stood at -$3.3 million in 2022, then jumped by 55.63% to -$1.5 million in 2023, then sank by 184.27% to -$4.1 million in 2024, then grew by 23.62% to -$3.2 million in 2025, then surged by 105.05% to $159944.0 in 2026.
• The last three EBT figures came in at $159944.0 (Q2 2026), -$1.3 million (Q1 2026), and -$3.2 million (Q4 2025), per Business Quant data.